Dana-Far­ber backed Neo­morph hunts 'un­drug­gable' pro­teins with new round of in­vestor cash for hires, de­vel­op­ment

Big in­vest­ments in pro­tein degra­da­tion, the process of un­lock­ing pre­vi­ous­ly “un­drug­gable” bind­ing sites for nov­el ther­a­peu­tics, are noth­ing new with some of phar­ma’s biggest play­ers al­ready dab­bling in the field. But a new biotech backed by the Dana-Far­ber Can­cer In­sti­tute be­lieves its “mol­e­c­u­lar glue” plat­form could help it stand out — and it’s got the fund­ing to test its hy­poth­e­sis.

Neo­morph, a biotech spe­cial­iz­ing in the buzzy field of pro­tein degra­da­tion, has snared a $105 mil­lion Se­ries A fi­nanc­ing round to scale up its R&D team and hunt for new med­i­cines in a range of ther­a­peu­tic ar­eas, par­tic­u­lar­ly on­col­o­gy, the com­pa­ny said Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.